Menu

Advantages of CAR-T Cell Therapy


What are some advantages of CAR-T cell therapy?

One of the major advantages of CAR-T cell therapy is the short treatment time needed – administered with a single infusion that may require at the most, two weeks of inpatient care, and then it’s done. Because aggressive chemotherapy is not used, most patients have a much more rapid recovery than after stem cell transplants in which aggressive chemotherapy is used. At some point in the future, CAR-T cell therapy may even replace most types of transplants but at the current time, CAR-T cell therapy is approved for the treatment of patients in whom transplant is not likely to be curative or in patients who relapse after transplant.

Clinical trials in blood cancers have shown that even in patients whose cancer came back after multiple treatments, CAR-T cell therapy helped them achieve remissions that lasted for years. Others can live longer without their cancer getting worse, and in some cases can then benefit from curative cancer treatment such as stem cell transplantation.

CAR-T cell therapy is also a “living drug”, and its benefits can last for many years. Since the cells can persist in the body long-term, they may recognize and attack cancer cells if and when there’s a relapse. The data is still evolving, but after 15 months, 42% of adult lymphoma patients who received CD19 CAR-T cell therapy were still in remission. And two-thirds of childhood acute lymphoblastic leukemia patients were still in remission after six months. These are patients whose cancers were deemed very aggressive and for whom other standards of care had failed.


To schedule an appointment please call 732-235-8515.

CAR T cells 

CAR T cells and TCR T cells are engineered to produce special receptors on their surfaces. They are then expanded in the laboratory and returned to the patient. Credit: National Cancer Institute

 

 

 

 

 

ScreenNJ

 

 

 

precision medicine at Rutgers Cancer Institute

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health